Summary
Altria Group, Inc. (MO) reported a significant increase in net earnings for the six months ended June 30, 2024, primarily driven by a substantial gain from the sale of its IQOS System commercialization rights, which contributed $2.7 billion to earnings before income taxes. Despite this large one-time gain, the company's adjusted net earnings saw a slight decrease of 4.1% compared to the prior year, reflecting a challenging operating environment. This was impacted by lower operating companies income (OCI) in the smokeable products segment due to declining shipment volumes and increased costs, and an asset impairment charge of $354 million related to the Skoal trademark in the oral tobacco products segment. While the company continues to navigate macroeconomic pressures and evolving consumer preferences, it has successfully executed substantial share repurchases funded by proceeds from its ABI investment sale, aiming to enhance shareholder value. The company also advanced its smoke-free future strategy with positive developments in its NJOY e-vapor business, including FDA marketing granted orders for menthol products. However, the company faces ongoing challenges from illicit e-vapor products and a general increase in illicit trade across tobacco categories, which management is actively monitoring.
Financial Highlights
49 data points| Revenue | $6.21B |
| Cost of Revenue | $1.60B |
| Gross Profit | $3.67B |
| Operating Income | $2.53B |
| Net Income | $3.80B |
| EPS (Basic) | $2.21 |
| EPS (Diluted) | $2.21 |
| Shares Outstanding (Basic) | 1.72B |
| Shares Outstanding (Diluted) | 1.72B |
Key Highlights
- 1Altria reported a significant increase in net earnings to $5.93 billion for the six months ended June 30, 2024, up from $3.90 billion in the prior year, largely due to a $2.7 billion pre-tax gain from the sale of IQOS System commercialization rights.
- 2Adjusted net earnings decreased by 4.1% to $4.28 billion for the six months ended June 30, 2024, compared to $4.46 billion in the prior year, indicating pressure on core operations.
- 3The company recorded a $354 million pre-tax impairment charge on the Skoal trademark due to declining sales volumes in the smokeless tobacco market.
- 4Altria repurchased $2.4 billion of its common stock under accelerated share repurchase agreements during the first quarter, funded by proceeds from the sale of a portion of its ABI investment.
- 5NJOY, Altria's e-vapor business, received FDA marketing granted orders for four menthol e-vapor products, and its U.S. e-vapor category share grew to 5.5% in the second quarter.
- 6The smokeable products segment experienced a 4.7% decrease in net revenues due to lower shipment volumes, despite pricing increases.
- 7The oral tobacco products segment saw a 4.1% increase in net revenues, driven by higher pricing, but reported OCI declined significantly due to the Skoal impairment charge.